Downregulation of BMP6 enhances cell proliferation and chemoresistance via activation of the ERK signaling pathway in breast cancer

Lian,Wen-Jing; Liu,Geng; Liu,Yuan-Jie; Zhao,Zhi-Wei; Yi,Tao; Zhou,Hong-Ying

doi:10.3892/or.2013.2462

Downregulation of BMP6 enhances cell proliferation and chemoresistance via activation of the ERK signaling pathway in breast cancer

Authors:
- Wen-Jing Lian
- Geng Liu
- Yuan-Jie Liu
- Zhi-Wei Zhao
- Tao Yi
- Hong-Ying Zhou
View Affiliations

Affiliations: Department of Human Anatomy, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Biotherapy Laboratory of Gynecological Oncology, Key Laboratory of Obstetric and Gynecologic and Pediatric Diseases and Birth Defects of the Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: May 14, 2013 https://doi.org/10.3892/or.2013.2462
Pages: 193-200

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies indicate that bone morphogenetic protein (BMP) 6 is involved in breast cancer development and progression. However, the mechanism underlying the role of BMP6 in breast cancer cell proliferation, differentiation and chemoresistance remains unknown. In this study, we confirmed that BMP6 expression was downregulated in breast cancer tissues compared with the adjacent normal breast tissues. We further demonstrated that the downregulation of BMP6 was correlated with the estrogen receptor (ER) and progesterone receptor (PR) status, tumor grade and enhanced proliferation (Ki67 proliferation index). In vitro functional experiments showed that the suppression of BMP6 expression by a specific small hairpin (sh)RNA vector led to increased proliferation in the MCF7 breast cancer cell line. Furthermore, knockdown of BMP6 in MCF7 cells enhanced the chemoresistance to doxorubicin by upregulation of mdr-1/P-gp expression and activation of the ERK signaling pathway. Taken together, our data suggest that BMP6 plays a critical role in breast cancer cell aberrant proliferation and chemoresistance and may serve as a novel diagnostic biomarker or therapeutic target for breast cancer.

View Figures

View References

1	Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
2	Gao H, Chakraborty G, Lee-Lim AP, et al: The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell. 150:764–779. 2012. View Article : Google Scholar : PubMed/NCBI
3	Cellurale C, Girnius N, Jiang F, et al: Role of JNK in mammary gland development and breast cancer. Cancer Res. 72:472–481. 2012. View Article : Google Scholar : PubMed/NCBI
4	Perrimon N, Pitsouli C and Shilo BZ: Signaling mechanisms controlling cell fate and embryonic patterning. Cold Spring Harb Perspect Biol. 4:a0059752012. View Article : Google Scholar : PubMed/NCBI
5	Guo J and Wu G: The signaling and functions of heterodimeric bone morphogenetic proteins. Cytokine Growth Factor Rev. 23:61–67. 2012. View Article : Google Scholar : PubMed/NCBI
6	Singh A and Morris RJ: The Yin and Yang of bone morphogenetic proteins in cancer. Cytokine Growth Factor Rev. 21:299–313. 2010. View Article : Google Scholar : PubMed/NCBI
7	Alarmo EL and Kallioniemi A: Bone morphogenetic proteins in breast cancer: dual role in tumourigenesis? Endocr Relat Cancer. 17:R123–R139. 2010. View Article : Google Scholar : PubMed/NCBI
8	Rhodes A, Jasani B, Barnes DM, et al: Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol. 53:125–130. 2000. View Article : Google Scholar
9	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
10	Deng S, Zhou H, Xiong R, et al: Over-expression of genes and proteins of ubiquitin specific peptidases (USPs) and proteasome subunits (PSs) in breast cancer tissue observed by the methods of RFDD-PCR and proteomics. Breast Cancer Res Treat. 104:21–30. 2007. View Article : Google Scholar : PubMed/NCBI
11	Zhou HY, Mei Y, Lu YG, et al: Application of restriction fragment differential display-polymerase chain reaction in study on differential expression profiles of human diseases. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 22:294–297. 2005.
12	Piccirillo SG and Vescovi AL: Bone morphogenetic proteins regulate tumorigenicity in human glioblastoma stem cells. Ernst Schering Found Symp Proc. 5:59–81. 2006.PubMed/NCBI
13	Bunyaratavej P, Hullinger TG and Somerman MJ: Bone morphogenetic proteins secreted by breast cancer cells upregulate bone sialoprotein expression in preosteoblast cells. Exp Cell Res. 260:324–333. 2000. View Article : Google Scholar : PubMed/NCBI
14	Shepherd TG, Thériault BL and Nachtigal MW: Autocrine BMP4 signalling regulates ID3 proto-oncogene expression in human ovarian cancer cells. Gene. 414:95–105. 2008. View Article : Google Scholar : PubMed/NCBI
15	Barekati Z, Radpour R, Lu Q, et al: Methylation signature of lymph node metastases in breast cancer patients. BMC Cancer. 12:2442012. View Article : Google Scholar : PubMed/NCBI
16	Zhang M, Wang Q, Yuan W, et al: Epigenetic regulation of bone morphogenetic protein-6 gene expression in breast cancer cells. J Steroid Biochem Mol Biol. 105:91–97. 2007. View Article : Google Scholar : PubMed/NCBI
17	Seckinger A, Meissner T, Moreaux J, Goldschmidt H, Fuhler GM, Benner A, et al: Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene. 28:3866–3879. 2009. View Article : Google Scholar
18	Takahashi M, Otsuka F, Miyoshi T, et al: Bone morphogenetic protein 6 (BMP6) and BMP7 inhibit estrogen-induced proliferation of breast cancer cells by suppressing p38 mitogen-activated protein kinase activation. J Endocrinol. 199:445–455. 2008. View Article : Google Scholar
19	Haudenschild DR, Palmer SM, Moseley TA, You Z and Reddi AH: Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer. Cancer Res. 64:8276–8284. 2004. View Article : Google Scholar : PubMed/NCBI
20	Wach S, Schirmacher P, Protschka M and Blessing M: Overexpression of bone morphogenetic protein-6 (BMP-6) in murine epidermis suppresses skin tumor formation by induction of apoptosis and downregulation of fos/jun family members. Oncogene. 20:7761–7769. 2001. View Article : Google Scholar : PubMed/NCBI
21	Coley HM: Mechanisms and consequences of chemotherapy resistance in breast cancer. Eur J Cancer. (Suppl 7): 3–7. 2009. View Article : Google Scholar
22	Drasin DJ, Robin TP and Ford HL: Breast cancer epithelial-to-mesenchymal transition: examining the functional consequences of plasticity. Breast Cancer Res. 13:2262011. View Article : Google Scholar : PubMed/NCBI
23	Chen GQ, Zhao ZW, Zhou HY, Liu YJ and Yang HJ: Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin. Med Oncol. 27:406–415. 2010. View Article : Google Scholar : PubMed/NCBI
24	Yang S, Du J, Wang Z, et al: Dual mechanism of deltaEF1 expression regulated by bone morphogenetic protein-6 in breast cancer. Int J Biochem Cell Biol. 41:853–861. 2009. View Article : Google Scholar : PubMed/NCBI
25	Yang S, Du J, Wang Z, et al: BMP-6 promotes E-cadherin expression through repressing deltaEF1 in breast cancer cells. BMC Cancer. 7:2112007. View Article : Google Scholar : PubMed/NCBI
26	Foroni C, Broggini M, Generali D and Damia G: Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact. Cancer Treat Rev. 38:689–697. 2012. View Article : Google Scholar : PubMed/NCBI
27	Zhang YE: Non-Smad pathways in TGF-beta signaling. Cell Res. 19:128–139. 2009. View Article : Google Scholar : PubMed/NCBI
28	Li B: Bone morphogenetic protein-Smad pathway as drug targets for osteoporosis and cancer therapy. Endocr Metab Immune Disord Drug Targets. 8:208–219. 2008. View Article : Google Scholar : PubMed/NCBI
29	Karam M, Legay C, Auclair C and Ricort JM: Protein kinase D1 stimulates proliferation and enhances tumorigenesis of MCF-7 human breast cancer cells through a MEK/ERK-dependent signaling pathway. Exp Cell Res. 318:558–569. 2012. View Article : Google Scholar
30	Shen H, Xu W, Luo W, et al: Upregulation of mdr1 gene is related to activation of the MAPK/ERK signal transduction pathway and YB-1 nuclear translocation in B-cell lymphoma. Exp Hematol. 39:558–569. 2011. View Article : Google Scholar : PubMed/NCBI
31	Guan J, Chen XP, Zhu H, Luo SF, Cao B and Ding L: Involvement of extracellular signal-regulated kinase/mitogen-activated protein kinase pathway in multidrug resistance induced by HBx in hepatoma cell line. World J Gastroenterol. 10:3522–3527. 2004.PubMed/NCBI